Label will be revised to stress precautions that the breast cancer therapy Herceptin (trastuzumab) be reconstituted with 20 mL of bacteriostatic water for injection as a diluent and that it be handled with caution during reconstitution. Genentech advised healthcare providers of the changes in a recent letter
You may also be interested in...
Genentech is revising Herceptin labeling to add warnings about fatal hypersensitivity, infusion and pulmonary reactions in breast cancer patients being treated with the anti-HER2 oncologic.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011